Randomised double-blind placebo-controlled study of lisdexamfetamine for the treatment of methamphetamine dependence

• Principal Investigator: Nicholas Lintzeris, University of Sydney
• Chief Investigator: Robert Ali, University of Adelaide
• Chief Investigator: Adrian Dunlop, University of Newcastle
• Chief Investigator: Nadine Ezard, St Vincent's Hospital Sydney
• Chief Investigator: Jason White, University of South Australia
• Chief Investigator: Rebecca McKetin, University of New South Wales
• Chief Investigator: Raimondo Bruno, University of Tasmania
• Chief Investigator: Andrew Carr, St Vincent's Centre for Applied Medical Research
• Chief Investigator: Kate Dolan, University of New South Wales

This project aligns with the following Sustainable Development Goals and Targets:

Ezard, N., Dunlop, A., Hall, M., Ali, R., L., McKetin, R., Bruno, R., Phung, N., Carr, A., White, J., Clifford, B., Liu, Z., Shanahan, M., Dolan, K., Baker, A. and Lintzeris, N. (2018). LiMA: a study protocol for a randomised, double blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. BMJ Open, 8, (7). doi:10.1136/bmjopen-2017-020723 [RJ1438] View web page